Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40‐week extension of the GUARD randomized study
Sang Youb Han; Sun Ae Yoon; Byoung Geun Han; Sung Gyun Kim; Young‐Il Jo; Kyung Hwan Jeong; Kook‐Hwan Oh; Hyeong Cheon Park; Sun‐Hee Park; Shin‐Wook Kang; Ki‐Ryang Na; Sun Woo Kang; Nam‐Ho Kim; Younghwan Jang; Bogyeong Kim; Seonghye Shin; Dae Ryong Cha
Author Information: Department of Internal Medicine
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.